IL38375A - Anaesthetic compositions comprising a solution of 3alpha-hydroxy-5alpha-pregnane-11,20-dione in organic solvent - Google Patents
Anaesthetic compositions comprising a solution of 3alpha-hydroxy-5alpha-pregnane-11,20-dione in organic solventInfo
- Publication number
- IL38375A IL38375A IL38375A IL3837571A IL38375A IL 38375 A IL38375 A IL 38375A IL 38375 A IL38375 A IL 38375A IL 3837571 A IL3837571 A IL 3837571A IL 38375 A IL38375 A IL 38375A
- Authority
- IL
- Israel
- Prior art keywords
- composition
- present
- water
- weight
- oil
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract 36
- DUHUCHOQIDJXAT-OLVMNOGESA-N 3-hydroxy-(3-α,5-α)-Pregnane-11,20-dione Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)C)[C@@]2(C)CC1=O DUHUCHOQIDJXAT-OLVMNOGESA-N 0.000 title claims abstract 7
- 230000003444 anaesthetic effect Effects 0.000 title claims abstract 4
- 239000003960 organic solvent Substances 0.000 title 1
- 239000007788 liquid Substances 0.000 claims abstract 14
- 239000003921 oil Substances 0.000 claims abstract 9
- 235000019198 oils Nutrition 0.000 claims abstract 9
- 150000002148 esters Chemical class 0.000 claims abstract 8
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract 7
- 229930195729 fatty acid Natural products 0.000 claims abstract 7
- 239000000194 fatty acid Substances 0.000 claims abstract 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract 6
- 239000000839 emulsion Substances 0.000 claims abstract 6
- -1 fatty acid esters Chemical class 0.000 claims abstract 5
- 150000004665 fatty acids Chemical class 0.000 claims abstract 5
- 150000003431 steroids Chemical class 0.000 claims abstract 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract 4
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 claims abstract 4
- DCAYPVUWAIABOU-UHFFFAOYSA-N hexadecane Chemical compound CCCCCCCCCCCCCCCC DCAYPVUWAIABOU-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000000243 solution Substances 0.000 claims abstract 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims abstract 4
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract 3
- 239000003795 chemical substances by application Substances 0.000 claims abstract 3
- 238000002347 injection Methods 0.000 claims abstract 3
- 239000007924 injection Substances 0.000 claims abstract 3
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract 3
- JNYAEWCLZODPBN-KVTDHHQDSA-N (2r,3r,4r)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@@H](O)[C@H]1O JNYAEWCLZODPBN-KVTDHHQDSA-N 0.000 claims abstract 2
- 150000001408 amides Chemical class 0.000 claims abstract 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims abstract 2
- 229940116333 ethyl lactate Drugs 0.000 claims abstract 2
- 125000005456 glyceride group Chemical group 0.000 claims abstract 2
- 229940074076 glycerol formal Drugs 0.000 claims abstract 2
- 229930195733 hydrocarbon Natural products 0.000 claims abstract 2
- 150000002430 hydrocarbons Chemical class 0.000 claims abstract 2
- 229940057995 liquid paraffin Drugs 0.000 claims abstract 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims abstract 2
- 229940094933 n-dodecane Drugs 0.000 claims abstract 2
- 229960003966 nicotinamide Drugs 0.000 claims abstract 2
- 235000005152 nicotinamide Nutrition 0.000 claims abstract 2
- 239000011570 nicotinamide Substances 0.000 claims abstract 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims abstract 2
- 229940032094 squalane Drugs 0.000 claims abstract 2
- 239000003381 stabilizer Substances 0.000 claims abstract 2
- 150000005846 sugar alcohols Polymers 0.000 claims abstract 2
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract 2
- 239000008158 vegetable oil Substances 0.000 claims abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 7
- 125000006353 oxyethylene group Chemical group 0.000 claims 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- 230000001419 dependent effect Effects 0.000 claims 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims 2
- 239000004530 micro-emulsion Substances 0.000 claims 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims 1
- 235000003911 Arachis Nutrition 0.000 claims 1
- 244000105624 Arachis hypogaea Species 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 239000004215 Carbon black (E152) Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 235000010469 Glycine max Nutrition 0.000 claims 1
- 244000068988 Glycine max Species 0.000 claims 1
- 240000008042 Zea mays Species 0.000 claims 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 239000003240 coconut oil Substances 0.000 claims 1
- 235000019864 coconut oil Nutrition 0.000 claims 1
- 235000005822 corn Nutrition 0.000 claims 1
- 235000012343 cottonseed oil Nutrition 0.000 claims 1
- 239000002385 cottonseed oil Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000010685 fatty oil Substances 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims 1
- SXQFCVDSOLSHOQ-UHFFFAOYSA-N lactamide Chemical compound CC(O)C(N)=O SXQFCVDSOLSHOQ-UHFFFAOYSA-N 0.000 claims 1
- 239000006193 liquid solution Substances 0.000 claims 1
- 229940049964 oleate Drugs 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 150000003904 phospholipids Chemical class 0.000 claims 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 150000002191 fatty alcohols Chemical class 0.000 abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 125000005907 alkyl ester group Chemical group 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008121 dextrose Substances 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 229940051841 polyoxyethylene ether Drugs 0.000 abstract 1
- 229920000056 polyoxyethylene ether Polymers 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
1379730 Steroid anaesthetic compositions GLAXO LABORATORIES Ltd 16 Dec 1971 [17 Dec 1970] 60067/70 Heading ASB An anaesthetic composition suitable for use by injection comprises 3a-hydroxy-5a-pregnane-11, 20-dione in solution in an inert organic liquid injection medium. Water-soluble organic liquids may be employed, in which case water may be present in the solution. Specified watersoluble organic liquids are C 1 -C 6 diof polyhydric alcohols, glycerol formal, water-soluble amides (e.g. nicotinamide or N-#-hydroxyethyl lactomide) and water-soluble esters, e.g. ethyl lactate. Alternatively, water-insoluble organic liquids may be employed, especially oils such as fatty alcohols and their esters, fatty acid esters (including alkyl esters of fatty acids and vegetable oils) and hydrocarbons (including liquid paraffin, squalane, n-dodecane, n-hexadecane). Such oil solutions of steroid may be employed in the form of an aqueous emulsion wherein the oil is the continuous of the disperse phase. Such emulsions may contain a surface active component, e.g. a polyoxyethylated derivative of a fatty glyceride oil, a polyoxyethylene ether of a fatty alcohol, or polyoxyethylenepolyoxypropylene ether, a polyoxyethylated fatty acid ester of sorbiton or mannitan, a polyethylene glycol ester of a fatty acid or a phospholified. Additional ingredients which may be present are emulsion stabilising agents, surface disordering agents and additional steroids. Water-soluble substances such as dextrose, glycerol and sodium chloride, serving to render the compositions approximately isotonic with blood, may also be present. The composition may be made up in unit dosage form. (From GB1379730 A) [FR2118120A1]
Claims (1)
1. What we claim is:- 1. A composition adapted for use in medicine by injection as an anaesthetic comprising 3a-hydrox.y-5a-pregnane-ll , 20-dione in solutio in an inert organic liquid medium, as herein defined.1 2. A composition as claimed in claim 1 in the form of a solution also containing water. 3. A composition as claimed in either of claims 1 or 2. wherein the inert organic liquid medium comprises a polyhydric alcohol, a water soluble ester, or a water-soluble amide. 4. A composition as claimed in any of the. preceding claims wherein the inert organic liquid medium comprises propylene glycol, glycerol, ethyl lactate, N-^-hydroxyethyl)lactamide, glycerol formal or nicotinamide . 5. A composition as claimed in any one of claims 2 to 4 wherein 3cc~hydroxy- Sa-pregnane- 11 , 20-dione is present in an amount of 0.1-4% by weight. 6. A composition as claimed in claim 1 in the form of a non-aqueous solution. 7. A composition as claimed in claim o wherein the inert organic liquid, medium is an oil. 8. A composition as claimed in claim 7 wherein the inert organic liquid medium is an aliphatic alcohol having 10-15 carbon atoms or an ester thereof with an aliphatic carboxylic acid having 1-6 carbon atoms, an ester of a fatty acid having 12-18 carbon atoms, a hydrocarbon oil, or a vegetable oil . 9. A composition as claimed in claim 8 wherein the inert organic liquid medium is tridecyl or isopropyl myristate, isopropyl palmitate, ethyl or n-octyl oleate, liquid paraffin, n-dodecane, n-hexadecane, squalane, coconut oil, castor oil, corn 011, arachis oil, soyabean oil, or cottonseed oil. 10. A composition as claimed in any one of claims 6 to 9 wherein the 3a--hydroxy-5a-pregnane-ll , 20-dione is present in an amount of 0.1 to 3% by weight. llt, A composition as claimed in claim 1 in the form of an emulsion or micro-emulsion comprising a continuous phase comprising a water-immiscible inert organic liquid solution as claimed in any one of claims 7 to 9 and additional Av ter. 12. A composition as claimed in claim 1 in the form o an emulsio wherein the disperse phase comprises a water-immiscible inert organic liquid medium as defined in any one of claim 7 to 9 and the continuous phase comprises water. 13. A composition as claimed in claim 12 wherein a parenterally acceptable surface active component having an HLB value of Q.JtL.1 - at least 9, optionally 9-15, is present.' 14. A composition as claimed in claim 13 wherein the surface active component comprises a polyoxy-ethylated derivative of a fatty glyceride oil (having 12-20 carbon atoms) and containing 35-45 oxyethylene groups per mole of fatty oil; a polyoxyeth lene ether of an alcohol having 12-1.8 carbon atoms and containing 10-30 oxyethylene groups; a polyoxyethylene-polyoxypropylene ether containing 15-150 oxyethylene groups and 15-50 oxypropylene groups; a polyoxyethylated fatty acid (having 12-18 carbon atoms) ester of sorbitan or mannitan containing 15-30 oxyethylene groups; a polyethylene glycol ester of a fatty acid (having 12-18 carbon atotas) and containing 6-40 oxyethylene groups: or a phospholipid. 15. A composition as claimed in any one of claims 12 -33- 14 wherein a parenterally acceptable surface active component having an HLB value of 3 to '8 is additionally present as an emulsion stabilising agent. 1 16. A composition as claimed in any one of claims 12 to 15 wherein the inert organic liquid medium is present in an amount of 5 to 50% by weight. 17. A composition as claimed in any one of claims 12 to 16 wherein the surface active component is present in an amount 0.1 to 5%. by weight. 18. A composition as claimed in any one of claims 12 to 17 wherein the droplet size of the emulsion is less than 5 μπι. 19. A composition as claimed in any one of claims 12 to 18. wherein the 3a-hydroxy-5a-pregnane-ll , 20-dione is present in an amount of 0.1 to 2.5% by weight. 20. A composition as claimed in claim 1 in the form of a micro-emulsion wherein the dispersed phase comprises a water-immiscible inert organic, liquid medium as defined in any one of claims 7 to and the continuous phase comprises water. 21. A composition as claimed in claim 20 wherein a surface active component as defined in claim 13 or claim 14 is present. 22 . A composition as claimed in claim 20 or claim 21 wherein an aliphatic alcohol having at least 12 carbon atoms or a polyethylene glycol having a molecular weight of at least 4000 is present as a surface disordering agent. 23. A composition as claimed in an}' one of claims 20 to 22 wherein the surface active component and the surface disordering agent content is from 5 to 60% by weight. 24 . A composition as claimed in any one of claims 20 to 23 wherein the inert organic liquid medium is present in an amount of 5 to 30% by weight. 25 . A composition as claimed in any one of claims 20 to 24 wherein the 3a-hydroxy- 5a-pregnane- 11 , 20-dione is present in an amount of 0. 1 to 0. 6% by weight. 26 . A composition as claimed in any one of claims 1 to A , 6 to 9 , 1 1 to 18 , or 20 to 24 wherein a second of formula II, herein defined, steroid of the 5oc - regnane series ,/ having a 3a -hydroxy group, an oxo group at the 11 and 20 positions, j>5 1 and a group of the formula OR at the 21 position (where R is alkanoyl group having a straight or branched chain which may substituted or unsubstituted by a j^up_r_i^^l-iia_ ^erLL. carbooyl group or a benzoyl group, is also present. 27. A. composition as claimed in claim 26 wherein R is an acetyl group. 28. A composition as claimed in claim 26 or claim 27 wherein the weight ratio of said second steroid to the 3a-hydroxy-5<'i-pregnane-ll , 20-dione is from 1:20 to 1:1. 29. A composition as claimed in any one of claims 26 to 28 when dependent on any one of claims 2 to , wherein the 3a-hydroxy-5a-pregnane- 11 , 20-dione is present in an amount of 0.5 to 10% by weight. 30. A composition as claimed in any one of claims 26 to 28 when dependent on any one of claims & to 9. wherein the 3 31. A composition as claimed in any one of claims 26 to 2.8 when dependent on any one of claims 12 to 18, wherein the 3a-hydroxy- 5a -pregnane- 11 , 20-dione is present in an amount of 0.3 to 12% by weight. - 36
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB6006770A GB1379730A (en) | 1970-12-17 | 1970-12-17 | Pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL38375A0 IL38375A0 (en) | 1972-02-29 |
| IL38375A true IL38375A (en) | 1976-07-30 |
Family
ID=10484946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL38375A IL38375A (en) | 1970-12-17 | 1971-12-16 | Anaesthetic compositions comprising a solution of 3alpha-hydroxy-5alpha-pregnane-11,20-dione in organic solvent |
Country Status (11)
| Country | Link |
|---|---|
| AT (1) | AT333963B (en) |
| AU (1) | AU471022B2 (en) |
| BE (1) | BE776788A (en) |
| CA (1) | CA970281A (en) |
| DE (1) | DE2162593A1 (en) |
| FR (1) | FR2118120B1 (en) |
| GB (1) | GB1379730A (en) |
| IE (1) | IE36705B1 (en) |
| IL (1) | IL38375A (en) |
| NL (1) | NL7117255A (en) |
| ZA (1) | ZA718463B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5581735A (en) * | 1978-12-14 | 1980-06-20 | Kao Corp | Emulsifier composition |
| JP2655190B2 (en) * | 1989-06-21 | 1997-09-17 | エスエス製薬 株式会社 | Ointment containing corticosteroid |
| SE9302295D0 (en) * | 1993-07-02 | 1993-07-02 | Kabi Pharmacia Ab | NEW PHARMACEUTICAL COMPOSITION |
| US6787530B1 (en) | 1996-08-23 | 2004-09-07 | Monash University | Use of pregnane-diones as analgesic agents |
| AU2019396217A1 (en) * | 2018-12-10 | 2021-07-08 | Halo Science LLC | Stable formulations of anesthetics and associated dosage forms |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL91070C (en) * | 1900-01-01 | |||
| DE1262509B (en) * | 1962-04-19 | 1968-03-07 | Hoechst Ag | Process for the production of aqueous solutions of steroid hormones |
| FR6555M (en) * | 1967-05-03 | 1968-12-23 |
-
1970
- 1970-12-17 GB GB6006770A patent/GB1379730A/en not_active Expired
-
1971
- 1971-12-16 BE BE776788A patent/BE776788A/en unknown
- 1971-12-16 NL NL7117255A patent/NL7117255A/xx unknown
- 1971-12-16 AU AU36959/71A patent/AU471022B2/en not_active Expired
- 1971-12-16 IL IL38375A patent/IL38375A/en unknown
- 1971-12-16 IE IE1595/71A patent/IE36705B1/en unknown
- 1971-12-16 AT AT1082571A patent/AT333963B/en not_active IP Right Cessation
- 1971-12-16 CA CA130,273A patent/CA970281A/en not_active Expired
- 1971-12-16 DE DE19712162593 patent/DE2162593A1/en active Pending
- 1971-12-16 FR FR7145228A patent/FR2118120B1/fr not_active Expired
- 1971-12-17 ZA ZA718463A patent/ZA718463B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL38375A0 (en) | 1972-02-29 |
| ATA1082571A (en) | 1976-04-15 |
| FR2118120B1 (en) | 1976-04-16 |
| AU471022B2 (en) | 1976-04-08 |
| GB1379730A (en) | 1975-01-08 |
| ZA718463B (en) | 1973-08-29 |
| BE776788A (en) | 1972-06-16 |
| CA970281A (en) | 1975-07-01 |
| IE36705B1 (en) | 1977-02-02 |
| AT333963B (en) | 1976-12-27 |
| DE2162593A1 (en) | 1972-07-06 |
| FR2118120A1 (en) | 1972-07-28 |
| AU3695971A (en) | 1973-06-21 |
| NL7117255A (en) | 1972-06-20 |
| IE36705L (en) | 1972-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1080623A (en) | Water-oil emulsion with stearates and glycerides | |
| US4551480A (en) | Compositions for the treatment of psoriasis | |
| KR870004699A (en) | Microemulsion composition moisturizes the skin | |
| DE69427185T2 (en) | Phase-pen colloids for use as ultrasound contrast agents | |
| US4254105A (en) | Multiple emulsion having a form of water/oil/water phase and process for preparation thereof, and multiple emulsion type cosmetics | |
| Becher | Nonionic surface-active compounds. X. Effect of solvent on micellar properties | |
| KR20170122282A (en) | Topical pharmaceutical composition based on semifluorinated alkanes | |
| Dickinson et al. | Preparation of fine protein-stabilized water-in-oil-in-water emulsions | |
| CN103110582A (en) | Cannabis phenolic compound microemulsion and preparation method thereof | |
| IL38375A (en) | Anaesthetic compositions comprising a solution of 3alpha-hydroxy-5alpha-pregnane-11,20-dione in organic solvent | |
| KR910005760A (en) | Insecticide and / or Acaricide Composition | |
| DD203464A5 (en) | PROCESS FOR PREPARING IMPROVED OIL-IN-WATER FORMULATION OF 9- (2-HYDROXY-AETHOXYMETHYL) GUANINE FOR LOCAL APPLICATION | |
| JPH09510692A (en) | Water-in-oil lotion containing corticosteroids | |
| NO950895L (en) | Pharmaceutical oil-in-water emulsion with antiviral activity containing 9 - [(2-hydroxyethoxy) methylAguanidine (acyclovir) or a salt or ester thereof | |
| IE35203B1 (en) | Steroid-containing pharmaceutical preparations | |
| US5635497A (en) | Topical application compositions | |
| Sari et al. | Isotropic systems of medium‐chain mono‐and diglycerides for solubilization of lipophilic and hydrophilic drugs | |
| JPS62223163A (en) | Urea-containing composition | |
| Frank et al. | Determination of micellar weights for di-alkyl sodium sulfosuccinates in anhydrous and hydrous hydrocarbon solutions | |
| Baboota et al. | Submicron size formulation of linseed oil containing omega-3 fatty acid for topical delivery | |
| JP2009542782A (en) | Injectable sustained release formulation of active ingredient and method for its preparation | |
| CA2529489A1 (en) | Transnasal microemulsions containing diazepam | |
| KR850000969A (en) | Process for preparing etophenamate-containing formulation | |
| FI79941B (en) | BLANDNINGAR FOER LOKAL ANVAENDNING PAO HUDEN. | |
| US3322624A (en) | Low temperature resistant aerosol anesthetic preparation containing benzocaine |